Fasciculation analysis reveals a novel parameter that correlates with predicted survival in amyotrophic lateral sclerosis
Introduction Prognostic uncertainty in amyotrophic lateral sclerosis (ALS) confounds clinical management planning, patient counseling, and trial stratification. Fasciculations are an early clinical hallmark of disease and can be quantified noninvasively. Using an innovative analytical method, we cor...
Saved in:
Published in | Muscle & nerve Vol. 63; no. 3; pp. 392 - 396 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.03.2021
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction
Prognostic uncertainty in amyotrophic lateral sclerosis (ALS) confounds clinical management planning, patient counseling, and trial stratification. Fasciculations are an early clinical hallmark of disease and can be quantified noninvasively. Using an innovative analytical method, we correlated novel fasciculation parameters with a predictive survival model.
Methods
Using high‐density surface electromyography, we collected biceps recordings from ALS patients on their first research visit. By accessing an online survival prediction tool, we provided eight clinical and genetic parameters to estimate individual patient survival. Fasciculation analysis was performed using an automated algorithm (Surface Potential Quantification Engine), with a Cox proportional hazards model to calculate hazard ratios.
Results
The median predicted survival for 31 patients was 41 (interquartile range, 31.5‐57) months. Univariate hazard ratios were 1.09 (95% confidence interval [CI], 1.03‐1.16) for the rate of change of fasciculation frequency (RoCoFF) and 1.10 (95% CI, 1.01‐1.19) for the amplitude dispersion rate. Only the RoCoFF remained significant (P = .04) in a multivariate model.
Discussion
Noninvasive measurement of fasciculations at a single time‐point could enhance prognostic models in ALS, where higher RoCoFF values indicate shorter survival. |
---|---|
Bibliography: | Funding information Engineering and Physical Sciences Research Council's Centre for Doctoral Training in Neurotechnology for Life and Health; Medical Research Council / Motor Neurone Disease Association, Grant/Award Number: MR/P000983/1; Sattaripour Charitable Foundation and the Motor Neurone Disease Association, Grant/Award Number: Shaw/Jul15/932‐794; Motor Neurone Disease Association ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0148-639X 1097-4598 |
DOI: | 10.1002/mus.27139 |